Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth
Blockbuster Obesity Treatment To Face New Rival This Year
Executive Summary
Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.
You may also be interested in...
Top 10 Best-Selling Drugs Of Q1 2023: Keytruda Topples Humira
A review of the top-selling drugs of the first quarter of 2023 demonstrate the declining turnover from products to treat or prevent COVID-19, as well as a precipitative drop by Humira. Merck & Co’s PD-1 inhibitor Keytruda grew strongly, and Novo Nordisk’s injectable diabetes drug Ozempic burst into the top 10 ranks.
With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.
Novo Nordisk Puts $2.3bn Into Manufacturing, But Won’t Aid Wegovy Supply Woes
Company says its new API production facility in Denmark will come online in 2029 and help meet demand for pipeline products in serious chronic diseases. Novo is currently contending with supply crunches for its semaglutide products.